Show simple item record

dc.contributor.authorWalensky, Rochelle P.en_US
dc.contributor.authorJacobsen, Margo M.en_US
dc.contributor.authorBekker, Linda-Gailen_US
dc.contributor.authorParker, Robert A.en_US
dc.contributor.authorWood, Robinen_US
dc.contributor.authorResch, Stephen C.en_US
dc.contributor.authorHorstman, N. Kayeen_US
dc.contributor.authorFreedberg, Kenneth A.en_US
dc.contributor.authorPaltiel, A. Daviden_US
dc.date.accessioned2016-05-02T17:02:11Z
dc.date.issued2015en_US
dc.identifier.citationWalensky, Rochelle P., Margo M. Jacobsen, Linda-Gail Bekker, Robert A. Parker, Robin Wood, Stephen C. Resch, N. Kaye Horstman, Kenneth A. Freedberg, and A. David Paltiel. 2015. “Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.” The Journal of Infectious Diseases 213 (10): 1523-1531. doi:10.1093/infdis/jiv523. http://dx.doi.org/10.1093/infdis/jiv523.en
dc.identifier.issn0022-1899en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26860302
dc.description.abstractBackground. For young South African women at risk for human immunodeficiency virus (HIV) infection, preexposure prophylaxis (PrEP) is one of the few effective prevention options available. Long-acting injectable PrEP, which is in development, may be associated with greater adherence, compared with that for existing standard oral PrEP formulations, but its likely clinical benefits and additional costs are unknown. Methods. Using a computer simulation, we compared the following 3 PrEP strategies: no PrEP, standard PrEP (effectiveness, 62%; cost per patient, $150/year), and long-acting PrEP (effectiveness, 75%; cost per patient, $220/year) in South African women at high risk for HIV infection (incidence of HIV infection, 5%/year). We examined the sensitivity of the strategies to changes in key input parameters among several outcome measures, including deaths averted and program cost over a 5-year period; lifetime HIV infection risk, survival rate, and program cost and cost-effectiveness; and budget impact. Results. Compared with no PrEP, standard PrEP and long-acting PrEP cost $580 and $870 more per woman, respectively, and averted 15 and 16 deaths per 1000 women at high risk for infection, respectively, over 5 years. Measured on a lifetime basis, both standard PrEP and long-acting PrEP were cost saving, compared with no PrEP. Compared with standard PrEP, long-acting PrEP was very cost-effective ($150/life-year saved) except under the most pessimistic assumptions. Over 5 years, long-acting PrEP cost $1.6 billion when provided to 50% of eligible women. Conclusions. Currently available standard PrEP is a cost-saving intervention whose delivery should be expanded and optimized. Long-acting PrEP will likely be a very cost-effective improvement over standard PrEP but may require novel financing mechanisms that bring short-term fiscal planning efforts into closer alignment with longer-term societal objectives.en
dc.language.isoen_USen
dc.publisherOxford University Pressen
dc.relation.isversionofdoi:10.1093/infdis/jiv523en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837902/pdf/en
dash.licenseLAAen_US
dc.subjectHIVen
dc.subjectpreexposure prophylaxisen
dc.subjectcost-effectivenessen
dc.subjectSouth Africaen
dc.subjectlong-acting agentsen
dc.titlePotential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infectionen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalThe Journal of Infectious Diseasesen
dash.depositing.authorWalensky, Rochelle P.en_US
dc.date.available2016-05-02T17:02:11Z
dc.identifier.doi10.1093/infdis/jiv523*
dash.contributor.affiliatedParker, Robert
dash.contributor.affiliatedFreedberg, Kenneth
dash.contributor.affiliatedWalensky, Rochelle


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record